Printer Friendly

CELL GENESYS FILES FOR STOCK OFFERING

 FOSTER CITY, Calif., Nov. 1 /PRNewswire/ -- Cell Genesys, Inc. (NASDAQ: CEGE) today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed offering of 2,000,000 shares of common stock. All of the shares offered are being sold by the company. The company has granted the underwriters an option to purchase up to an additional 300,000 shares to cover over- allotments, if any.
 CS First Boston, Invemed Associates, Inc. and Oppenheimer & Co. will co-manage the stock offering.
 Net proceeds to the company from the proposed sale of shares will be used to fund expanded research and development, capital expenditures related to the expansion of facilities and for other general corporate purposes.
 Cell Genesys is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products.
 A copy of the preliminary prospectus may be obtained from CS First Boston (Attention: New Issues Processing), 55 East 52nd Street, New York, NY 10055, 212-909-2000; Invemed Associates, Inc., 375 Park Avenue, Suite 2205, New York, NY 10152, 212-421-2500; and Oppenheimer & Co., Inc., Oppenheimer Tower - World Financial Center, New York, NY 10281, 212-667-7000.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 -0- 11/01/93
 /CONTACT: Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys, 415-358-9600, ext. 212/
 (CEGE)


CO: Cell Genesys, Inc. ST: California IN: MTC SU: OFR

MP -- NY010 -- 9056 11/01/93 10:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1993
Words:380
Previous Article:ALPHA-BETA TECHNOLOGY FILES REGISTRATION STATEMENT WITH SEC FOR PUBLIC OFFERING OF 1,300,000 SHARES OF COMMON STOCK
Next Article:EMERY WORLDWIDE WINS U.S. POSTAL SERVICE CONTRACT FOR AIR TRANSPORTATION OF CHRISTMAS MAIL
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters